Chronic Subdural Hematoma Clinical Trial
Official title:
To Scan or Not to Scan: The Role of Follow-up CT Scanning for Management of Chronic Subdural Hematoma After Neurosurgical Evacuation - a Prospective, Randomized, Controlled Trial
Chronic subdural hematoma (CSH) is one of the most common bleedings of the head. These
hematomas develop after minor head trauma and increase in size over weeks. Patients usually
present with headaches, gait disturbances, language problems or confusion. The state of the
art treatment of a symptomatic chronic subdural hematoma is to remove the hematoma by burr
hole trepanation.
The optimal follow-up for operated patients remains controversial. Due to the known high
rate of a second hematoma at the same place (usually within weeks), one strategy is to
perform serial computer tomography scans in order to identify recurrent hematomas early. The
radiologic evidence of a second hematoma often leads to reoperation, even if the patient has
no, or just slight symptoms. Another strategy after surgical hematoma evacuation is to
closely follow the patient with neurological examinations and perform neuroimaging only in
case of new symptoms. Advocators of this strategy argue that a follow-up with routine CT
scans may be harmful due to additional and maybe unnecessary surgeries and hospital days in
a patient population marked by advanced age and fragility.
The aim of the current study is to evaluate the role of computer tomography scanning in the
postoperative follow-up after removal of a chronic subdural hematoma. Participants of this
study will be allocated by chance to one of two study groups: Patients allocated to group A
will receive a computer tomography scan on day 2 and again on day 30 after surgery in
addition to a clinical examination. Patients allocated to group B will be examined
clinically on day 2 and day 30 without computer tomography. All patients will undergo a
final clinical examination after 6 months. The study will recruit 400 patients.
Background
Chronic subdural hematoma (CSH) is one of the most common intracranial bleedings in patients
over 60 years of age and a frequently found neurosurgical entity. Age related brain atrophy
leads to enlargement of the subarachnoid space, a space limited by the dura mater and the
arachnoid membrane. Blood vessels that occupy this space are being stretched and may rupture
after a minor head trauma. Although the resulting bleeding itself is often without
noticeable consequence for the patient, the anatomical outcome may be serious as it enlarges
the subdural space. The formation of new leaky capillary-like vessels and/or volume
enhancing osmotic gradients lead to the enlargement of the subdural hematoma over weeks,
filling the intracranial space and compressing the brain. Headaches, gait disturbances,
language problems, hemiparesis and decreased consciousness are among the many presenting
symptoms and tend to develop over days or weeks.
Computed tomography (CT) scan or magnetic resonance imaging (MRI) of the head typically
reveals the blood accumulation in the subdural space. Standard treatment includes the
evacuation of the subdural blood through burr holes (see below) under either local or
general anesthesia. In cases when a hematoma clot cannot be evacuated through burr holes a
small craniotomy is performed. CSH is feared for its high recurrence rate (between 9 and
27%) that mostly occurs within 3 months of the initial operation.
The optimal follow-up course for operated patients remains controversial. Due to the high
rate of recurrences, one strategy is to perform serial CT scans in order to identify
recurrent hematomas early. The radiologic evidence of a recurrent or significant persistent
hematoma often leads to reoperation. Another strategy after surgical hematoma evacuation is
to closely follow the patient with neurological examinations and perform neuroimaging only
in case of persistent or new neurologic deficits. Advocators of this strategy argue that
follow up with routine CT scans may be harmful due to additional and maybe unnecessary
surgeries and hospital days in a patient population marked by advanced age and fragility.
However, even when neuroimaging is done routinely, no correlation has been observed between
the radiologic evidence of a hematoma remnant and the reoperation rate. This observation has
been reported by Mori and Maeda in a retrospective analysis of 500 patients. Some persistent
hematoma is almost always seen after the surgical intervention and there seems to be a
correlation between the re-expansion rate of the brain and the likelihood of hematoma
recurrence. However, the correlation is weak and of little practical value for patient
treatment. The high incidence of hematoma remnants in post-op imaging complicates the
indication for re-operation of a recurrent CSH solely by imaging criteria. Since the
presence and the amount of remnant hematoma after the operation is a poor predictor of
future recurrent hematoma some clinicians refrain from postoperative CT scans and rely
solely on neurological assessments. If patients become symptomatic, serial CT scans are
performed and surgery is scheduled in cases of persistent, enlarging or new hematoma. The
discrepancy in follow-up strategy reflects our current incomplete understanding of the
pathophysiology of CSH and its recurrence.
The aim of the current study is to evaluate the role of CT scanning in the postoperative
treatment course after neurosurgical evacuation of CSH in a prospective, randomized
controlled trial.
Objective
The hypothesis of interest to test in this trial is that a follow-up protocol without any CT
scan is not inferior to a follow-up protocol with serial CT scans after neurosurgical
evacuation of CSH as assessed with the modified Rankin scale at 6 months. Additional
hypotheses of interest are that the size/volume/features of the hematoma rest/remnant in an
early (<72 hours) CT scan after neurosurgical evacuation is not correlated to the
neurological status of the patient and that the size/volume/features of the hematoma
rest/remnant on post-op CT scans is not predictive for reoperation.
Methods
Patients will be screened and included into this study within 48 hours after surgery for a
chronic subdural hematoma (burr hole trepanation and insertion of drainage). Study patients
are randomized (1:1) on day 2 after surgery into CT-Scan arm (group A) or Clinical arm
(group B). A CT scan is scheduled for patients of group A on day 2 and 30 after surgery.
Patients of both study groups (A and B) will receive a neurological follow-up examination at
day 2, 30 days and 6 months after surgery. Regardless of randomization all patients will
receive CT scanning if judged necessary on clinical grounds at any time.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06347796 -
Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study
|
N/A | |
Recruiting |
NCT04065113 -
Middle Meningeal Artery Embolization for Chronic Subdural Hematoma
|
N/A | |
Recruiting |
NCT02938468 -
Mgt of Chronic Subdural Hematoma Using Dexamethasone
|
Phase 2/Phase 3 | |
Completed |
NCT03307395 -
Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma
|
N/A | |
Terminated |
NCT04502745 -
A Study to Evaluate Endoscope-assisted, Minimally-invasive Cortical Access System for Chronic Subdural Evacuation
|
N/A | |
Terminated |
NCT03353259 -
Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery
|
Phase 2/Phase 3 | |
Recruiting |
NCT02568124 -
Tranexamic Acid in Chronic Subdural Hematomas
|
Phase 2/Phase 3 | |
Completed |
NCT02282228 -
Detecting Chronic Subdural Hematoma With Microwave Technology
|
N/A | |
Recruiting |
NCT05143216 -
High Concentration Oxygen Therapy for Pneumocephalus in Chronic Subdural Haematoma: A Prospective Observational Study
|
||
Active, not recruiting |
NCT04816591 -
Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA
|
N/A | |
Recruiting |
NCT06401772 -
The Effectiveness and Safety of Body Posture in Preventing Postoperative Recurrence for Chronic Subdural Hematoma
|
N/A | |
Completed |
NCT06134206 -
Burr Hole Ultrasound Study
|
N/A | |
Recruiting |
NCT03666949 -
General Anesthesia Versus Locoregional Anesthesia for Evacuation of Chronic Subdural Hematoma
|
N/A | |
Recruiting |
NCT03280212 -
Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma
|
Phase 3 | |
Completed |
NCT03447327 -
Outcome of Single Burr Hole Under Local Anaesthesia in the Management of Chronic Subdural Hematoma
|
N/A | |
Recruiting |
NCT05374681 -
Efficacy of a Minimally Invasive Therapy Adjuvant to the Standards of Care by Cyanoacrylate Embolization
|
N/A | |
Recruiting |
NCT05267184 -
Swedish Trial on Embolization of Middle Meningeal Artery Versus Surgical Evacuation in Chronic Subdural Hematoma
|
N/A | |
Not yet recruiting |
NCT05900557 -
Neurologic Deficits and Recovery in Chronic Subdural Hematoma
|
N/A | |
Completed |
NCT02757235 -
The Swedish Study of Irrigation Fluid Temperature in the Evacuation of Chronic Subdural Hematoma
|
N/A | |
Terminated |
NCT02111785 -
Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma
|
Phase 2/Phase 3 |